Stay updated with breaking news from Visual Function. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Researchers at the National Eye Institute (NEI) have developed the first patient-derived stem cell model for studying eye conditions related to
Researchers at the National Eye Institute have developed the first patient-derived stem cell model for studying eye conditions related to oculocutaneous albinism (OCA).
Clearside Biomedical, Inc. , a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that multiple presentations were given at the Retina Society 54 th Annual Scientific Meeting which took place September 29 October 2, 2021 in Chicago, IL. “These presentations demonstrate the targeted and ...
Scientists restore partial sight in blind man using optogenetic therapy Updated: Updated: May 25, 2021 12:58 IST During the tests, the patient was able to locate and touch a notebook on a table in front of him 92% of the time while wearing the goggles. Without them, he was unable to perform any visual task. Share Article AAA Experimental setup. Behavioral responses and brain activity were simultaneously recorded during the visual test. Credit: Sahel, JA., Boulanger-Scemama, E., Pagot, C. et al. Partial recovery of visual function in a blind patient after optogenetic therapy. Nat Med (2021). h...
Clearside Biomedical Featured in Multiple Data Presentations at the 44th Virtual Annual Macula Society Meeting Proprietary suprachoroidal injection platform demonstrates broad applicability across multiple retinal disorders CLS-AX will also be featured at the upcoming virtual Angiogenesis, Exudation, and Degeneration 2021 conference on February 13, 2021 Clearside Biomedical, Inc. , a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of … – Proprietary suprachoroidal injection platform demonstrates b...